Aliases & Classifications for Keratosis

MalaCards integrated aliases for Keratosis:

Name: Keratosis 12 44 15 73
Actinic Keratosis 73
Hyperkeratosis 73

Classifications:



External Ids:

Disease Ontology 12 DOID:161
MeSH 44 D007642
NCIt 50 C34747
SNOMED-CT 68 254666005

Summaries for Keratosis

Disease Ontology : 12 A skin disease characterized_by growth of keratin on the skin or mucous membranes.

MalaCards based summary : Keratosis, also known as actinic keratosis, is related to keratosis follicularis spinulosa decalvans, x-linked and keratosis, seborrheic, and has symptoms including exanthema, pruritus and trichorrhexis invaginata. An important gene associated with Keratosis is MBTPS2 (Membrane Bound Transcription Factor Peptidase, Site 2), and among its related pathways/superpathways are Developmental Biology and Keratinization. The drugs Aminolevulinic acid and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and kidney, and related phenotypes are Increased vaccinia virus (VACV) infection and growth/size/body region

Wikipedia : 76 Keratosis (from kerat- + -osis) is a growth of keratin on the skin or on mucous membranes stemming from... more...

Related Diseases for Keratosis

Diseases related to Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 227)
# Related Disease Score Top Affiliating Genes
1 keratosis follicularis spinulosa decalvans, x-linked 34.4 MBTPS2 SAT1
2 keratosis, seborrheic 34.4 FGFR3 KRT10 PIK3CA
3 keratosis follicularis spinulosa decalvans 34.4 LRP1 MBTPS2 SAT1
4 punctate palmoplantar keratoderma 32.4 AAGAB KRT10
5 ichthyosis vulgaris 32.0 FLG KRT1 KRT10
6 dermatosis papulosa nigra 31.9 FGFR3 PIK3CA
7 mal de meleda 31.5 KRT9 SERPINB7 SLURP1
8 palmoplantar keratoderma, epidermolytic 31.1 KRT1 KRT9
9 white sponge nevus 1 30.5 KRT1 KRT10 KRT9
10 striate palmoplantar keratoderma 30.4 CTSC DSG1 DSP KRT1 KRT10 SERPINB7
11 keratoacanthoma 30.4 DSG1 FLG KRT10
12 lichen planus 30.2 FLG IVL KRT10
13 alopecia 30.1 DSP GJA1 MBTPS2
14 discoid lupus erythematosus 29.7 FLG IVL KRT10
15 ainhum 29.7 GJA1 GJB2
16 palmoplantar keratosis 29.5 CTSC DSG1 DSP GJB2 KRT1 KRT9
17 acanthoma 29.5 KRT1 KRT10 KRT9
18 bullous pemphigoid 29.3 DSG1 DSP IVL
19 ichthyosis 29.0 FLG GJB2 KRT1 KRT10 MBTPS2
20 papilloma 28.9 FGFR3 FLG IVL KRT1 KRT10
21 congenital ichthyosiform erythroderma 28.8 FLG IVL KRT1 KRT10
22 epidermolytic hyperkeratosis 28.6 FLG KRT1 KRT10 KRT9
23 hypotrichosis 28.4 DSG1 GJA1 GJB2
24 actinic keratosis 12.4
25 keratosis pilaris atrophicans 12.3
26 inverted follicular keratosis 12.3
27 keratosis linearis with ichthyosis congenita and sclerosing keratoderma 12.3
28 keratosis follicularis, dwarfism, and cerebral atrophy 12.2
29 keratosis follicularis spinulosa decalvans, autosomal dominant 12.0
30 vulvar seborrheic keratosis 12.0
31 inflamed seborrheic keratosis 12.0
32 darier-white disease 12.0
33 keratosis palmoplantaris striata iii 11.9
34 keratosis palmoplantaris striata ii 11.9
35 keratosis palmaris et plantaris with clinodactyly 11.8
36 keratosis, familial actinic 11.8
37 keratosis, focal palmoplantar and gingival 11.8
38 onychogryposis, pedal, with keratosis plantaris and coarse hair 11.8
39 vulvar inverted follicular keratosis 11.8
40 circumscribed disseminated keratosis jadassohn lew type 11.8
41 keratosis palmoplantaris adenocarcinoma of the colon 11.8
42 papillon-lefevre syndrome 11.7
43 palmoplantar keratoderma, punctate type ia 11.6
44 haim-munk syndrome 11.6
45 erythrokeratodermia variabilis et progressiva 1 11.5
46 tyrosinemia, type ii 11.5
47 focal palmoplantar and gingival keratoderma 11.5
48 palmoplantar keratoderma i, striate, focal, or diffuse 11.2
49 epidermodysplasia verruciformis 11.1
50 tylosis with esophageal cancer 11.1

Comorbidity relations with Keratosis via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Keratosis, Seborrheic

Graphical network of the top 20 diseases related to Keratosis:



Diseases related to Keratosis

Symptoms & Phenotypes for Keratosis

UMLS symptoms related to Keratosis:


exanthema, pruritus, trichorrhexis invaginata

GenomeRNAi Phenotypes related to Keratosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased vaccinia virus (VACV) infection GR00249-S 9.62 FGFR3 FLG GJA1 GJB2 IVL KRT1

MGI Mouse Phenotypes related to Keratosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.73 DSG1 DSP FGFR3 GJA1 GJB2 KRT1
2 integument MP:0010771 9.36 DSP FGFR3 GJA1 GJB2 KRT1 LRP1

Drugs & Therapeutics for Keratosis

Drugs for Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
3
Fluorouracil Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 51-21-8 3385
4
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15307-86-5 3033
5
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
6
Alginic acid Approved, Investigational Phase 4 9005-32-7
7
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
8
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
9
Clobetasol Approved, Investigational Phase 4,Phase 2,Not Applicable 25122-46-7, 25122-41-2 32798 5311051
10
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
11
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2 185243-69-0
12
Amorolfine Approved, Investigational Phase 4 78613-35-1
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
14
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 2 91161-71-6 5402 1549008
15
Itraconazole Approved, Investigational Phase 4,Phase 3 84625-61-6 55283
16
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
17
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
18
Petrolatum Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 8009-03-8
19
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 69-72-7 338
20
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492
21
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
22
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
23
Menthol Approved Phase 4 2216-51-5 16666
24
Azathioprine Approved Phase 4 446-86-6 2265
25
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
26
Mycophenolic acid Approved Phase 4 24280-93-1 446541
27
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 11103-57-4, 68-26-8 445354
28
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Not Applicable 1406-16-2
30
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
31 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Radiation-Protective Agents Phase 4,Phase 2
39 Sunscreening Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
42 Antimetabolites, Antineoplastic Phase 4,Phase 3,Early Phase 1,Not Applicable
43 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
48 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
50 Anticholesteremic Agents Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 392)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
2 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
3 Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis Unknown status NCT01656226 Phase 4
4 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
5 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
6 Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
7 Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
8 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
9 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
10 Effects of Topical Diclofenac on Tumor Metabolism Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
11 Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
12 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) Completed NCT01000636 Phase 4
13 Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Completed NCT02251652 Phase 4 Ingenol Mebutate
14 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
15 Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
16 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
17 Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
18 Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
19 Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine
20 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
21 Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
22 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
23 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
24 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
25 Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
26 Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients Completed NCT00599807 Phase 4
27 Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails Completed NCT01703325 Phase 4 0.1% triamcinolone , 0.05% clobetasol propionate ointment
28 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
29 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
30 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
31 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
32 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
33 An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses Recruiting NCT03487588 Phase 4 A-101 Topical Solution
34 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Recruiting NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
35 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Recruiting NCT02866695 Phase 4 ingenol mebutate gel 0.015%
36 Treatment of Photodamaged Skin of the décolleté Recruiting NCT03573076 Phase 4
37 Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy Active, not recruiting NCT02990221 Phase 4 Ingenol mebutate
38 IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
39 Daylight-PDT With MAL for AK and Photodamaged Skin Active, not recruiting NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
40 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
41 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
42 Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
43 Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
44 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
45 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
46 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
47 Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses Unknown status NCT02473848 Phase 3 ingenol mebutate 500 ucg
48 Actinic Keratoses Treatment With Metvix® in Combination With Light Unknown status NCT02373371 Phase 3 Metvix®
49 T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
50 5fluorouracil for Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil

Search NIH Clinical Center for Keratosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: keratosis

Genetic Tests for Keratosis

Anatomical Context for Keratosis

MalaCards organs/tissues related to Keratosis:

41
Skin, Testes, Kidney, T Cells, Liver, Neutrophil, Bone

Publications for Keratosis

Articles related to Keratosis:

(show top 50) (show all 1226)
# Title Authors Year
1
Efficacy Endpoints in Clinical Trials in Actinic Keratosis. ( 29916197 )
2018
2
Photodynamic therapy corrects abnormal cancer-associated gene expression observed in actinic keratosis lesions and induces a remodeling effect in photodamaged skin. ( 29779986 )
2018
3
Novel mutation in MBTPS2 causes keratosis follicularis spinulosa decalvans in a large Chinese family. ( 29951998 )
2018
4
A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis. ( 29620004 )
2018
5
Comparison of 10 efficient protocols for photodynamic therapy of actinic keratosis: How relevant are effective light dose and local damage in predicting the complete response rate at 3 months? ( 29667728 )
2018
6
Reflectance confocal microscopy: a crucial role for actinic keratosis treatment monitoring. ( 29846971 )
2018
7
Successful Treatment of Actinic Keratosis with Kanuka Honey. ( 29955399 )
2018
8
Arsenical keratosis secondary to Fowler solution. ( 29387754 )
2018
9
A multi-centre, open, investigator initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0.015% on the face and scalp, and 0.05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT). ( 29355904 )
2018
10
Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. ( 29920789 )
2018
11
MART-1-Labeled Melanocyte Density and Distribution in Actinic Keratosis and Squamous Cell Cancer in situ: Pagetoid Melanocytes are a Potential Source of Misdiagnosis as Melanoma in Situ. ( 29943494 )
2018
12
Multiple Pigmented Seborrheic Keratosis with Sebaceous Differentiation - A Case Report. ( 28272654 )
2018
13
Differential proteomic analysis of actinic keratosis, Bowen's disease and cutaneous squamous cell carcinoma by label-free LC-MS/MS. ( 29665991 )
2018
14
Treatment of Grade II and III Actinic Keratosis Lesions with a Film-Forming Medical Device Containing Sunscreen/Piroxicam 0.8% and a Retinoic Acid/Glycolic Gel: A Pilot Trial. ( 29855896 )
2018
15
Topical formulations of delta-aminolevulinic acid for the treatment of actinic keratosis: Characterization and efficacy evaluation. ( 29407554 )
2018
16
Desmoglein 4 Mutation Underlies Autosomal Recessive Keratosis Pilaris Atrophicans. ( 29796690 )
2018
17
Photodynamic therapy with the use of superluminescent diodes (sLED) in the treatment of actinic keratosis. ( 29684690 )
2018
18
Treating actinic keratosis: assessment of effectiveness, discomfort, costs and follow-up. ( 29441544 )
2018
19
Daylight-Mediated Photodynamic Therapy With Methyl Aminolevulinate in Actinic Keratosis Treatment. ( 29351725 )
2018
20
The challenge of diagnosing seborrheic keratosis by reflectance confocal microscopy. ( 29797357 )
2018
21
A novel frameshift SERPINB7 mutation in a Chinese case with Nagashima-type palmoplantar keratosis: case report and review of the literature. ( 29888455 )
2018
22
Borst-Jadassohn phenomenon arising from a seborrhoeic keratosis and its characteristic dermoscopic features. ( 29888802 )
2018
23
Melanoma in situ mimicking a Lichen planus-like keratosis. ( 29350666 )
2018
24
Energy-based devices for actinic keratosis field therapy. ( 29894524 )
2018
25
Teledermatology-driven topical therapy of actinic keratosis: a comparative study of clinical effectiveness and compliance. ( 29797670 )
2018
26
Swiss (German) Version of the Actinic Keratosis Quality of Life questionnaire. ( 29669340 )
2018
27
Validity and Reliability of the Dutch Adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL). ( 29909413 )
2018
28
Daylight Photodynamic Therapy Versus 5-Fluorouracil for the Treatment of Actinic Keratosis: A Case Series. ( 29322431 )
2018
29
Treatment of Actinic Keratosis with Photodynamic Therapy Using Red or Green Light: A Comparative Study. ( 29963684 )
2018
30
Field-change actinic keratosis and immunosuppression: therapeutic options. ( 29668097 )
2018
31
Effectiveness and safety of 0.5% colchicine cream versus photodynamic therapy with methyl aminolevulinate in the treatment of actinic keratosis and skin field cancerisation of the forearms: a randomized controlled trial. ( 29862491 )
2018
32
Detection of human papillomavirus in actinic keratosis. ( 29383738 )
2018
33
Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis. ( 29442526 )
2018
34
Artemether for Topical Use in Patients with Seborrheic Keratosis. ( 29957837 )
2018
35
Actinic Keratosis and Non-Invasive Diagnostic Techniques: An Update. ( 29316678 )
2018
36
Daylight photodynamic therapy: experience in the treatment of actinic keratosis in San Gallicano Institute of Rome and a review of literature. ( 29368865 )
2018
37
Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response. ( 29356164 )
2018
38
Keratosis Punctata of the Palmar Creases. ( 29968049 )
2018
39
A follow-up report of acral melanoma in a patient with Nagashima-type palmoplantar keratosis: validation of SERPINB7 mutation and local recurrence. ( 29888704 )
2018
40
Diclofenac Sodium 3% in Hyaluronic Acid 2.5% Gel Significantly Diminishes the Actinic Keratosis Area and Severity Index. ( 29791916 )
2018
41
Correlations between histopathologic and dermoscopic findings in Korean actinic keratosis. ( 29676831 )
2018
42
Evaluation of T lymphocyte subpopulations in Actinic Keratosis, In Situ and Invasive Squamous Cell Carcinoma of the Skin. ( 29419888 )
2018
43
Self-expressed patient preferences for the treatment of actinic keratosis: results from a non-interventional study based on a real-life setting in Spain. ( 29402758 )
2018
44
Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients - a randomized intra-individual controlled trial. ( 28796885 )
2017
45
Prevalence of actinic keratosis in a French cohort of elderly people: the PROOF study. ( 28906092 )
2017
46
Acantholytic squamous cell carcinoma is usually associated with hair follicles, not acantholytic actinic keratosis, and is not "high risk": Diagnosis, management, and clinical outcomes in a series of 115 cases. ( 27889291 )
2017
47
Three cases of Nagashima-type palmoplantar keratosis associated with atopic dermatitis: A diagnostic pitfall. ( 29168226 )
2017
48
A seamless Phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp. ( 28078678 )
2017
49
In-clinic application of ingenol mebutate 0.015% gel for actinic keratosis in large areas of the face is feasible and attracts a high rate of patient satisfaction: Results of a questionnaire. ( 28776637 )
2017
50
Dermatoscopic Patterns of Nonfacial Actinic Keratosis: Characterization of Pigmented and Nonpigmented Lesions. ( 28538027 )
2017

Variations for Keratosis

Expression for Keratosis

Search GEO for disease gene expression data for Keratosis.

Pathways for Keratosis

GO Terms for Keratosis

Cellular components related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.43 DSP FLG GJA1 KRT1 KRT10 KRT9
2 connexin complex GO:0005922 9.37 GJA1 GJB2
3 lateral plasma membrane GO:0016328 9.33 DSG1 GJA1 GJB2
4 fascia adherens GO:0005916 9.26 DSP GJA1
5 cornified envelope GO:0001533 9.1 DSG1 DSP FLG IVL KRT1 KRT10
6 cytosol GO:0005829 10.1 AAGAB DSG1 FLG GJA1 GJB2 IVL
7 extracellular exosome GO:0070062 10.06 CTSC DSG1 DSP GJA1 IVL KRT1

Biological processes related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.63 DSG1 DSP IVL KRT1 KRT10 KRT9
2 epidermis development GO:0008544 9.62 ATP2A2 DSP FLG KRT9
3 keratinocyte differentiation GO:0030216 9.56 DSP FLG IVL KRT10
4 intermediate filament organization GO:0045109 9.43 DSP KRT9
5 gap junction assembly GO:0016264 9.4 GJA1 GJB2
6 epididymis development GO:1905867 9.37 GJA1 GJB2
7 peptide cross-linking GO:0018149 9.35 DSP FLG IVL KRT1 KRT10
8 cornification GO:0070268 9.17 DSG1 DSP FLG IVL KRT1 KRT10

Molecular functions related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.35 DSP FLG IVL KRT1 KRT10
2 gap junction channel activity GO:0005243 9.16 GJA1 GJB2
3 structural constituent of epidermis GO:0030280 8.8 FLG KRT1 KRT10

Sources for Keratosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....